Résumés
Abstract
In this paper, I outline some of the reasons why BRCA “previvors” (i.e., “survivors of a predisposition to cancer”) are different from previvors with other hereditary cancers. I examine how the absence of a standard of care for breast cancer risk for women with a BRCA mutation, coupled with a broad range of genetic penetrance and lower mortality, makes BRCA different than other hereditary cancers that have clear and established guidelines. In addition to these medical differences, social factors like the cultural prominence of breast cancer and the social significance of breasts have engendered a more complicated individual previvor identity for and cultural response to women with a BRCA mutation.
Keywords:
- previvor,
- BRCA,
- hereditary cancer,
- breast cancer
Résumé
Dans cet article, je décris quelques-unes des raisons pour lesquelles les « previvors » de BRCA (c-a-d. « survivants d’une prédisposition au cancer ») sont différents des previvors avec d’autres cancers héréditaires. J’examine comment l’absence d’une norme de soins pour le risque de cancer du sein chez les femmes ayant une mutation BRCA, associée à un large éventail de pénétration génétique et une mortalité plus faible, rend le BRCA différent des autres cancers héréditaires qui ont des directives claires et établies. En plus de ces différences médicales, des facteurs sociaux tels que la prééminence culturelle du cancer du sein et la signification sociale des seins ont engendré une identité prédictive individuelle plus complexe et une réponse culturelle aux femmes ayant une mutation BRCA.
Mots-clés :
- previvor,
- BRCA,
- cancer héréditaire,
- cancer du sein
Veuillez télécharger l’article en PDF pour le lire.
Télécharger
Parties annexes
Bibliography
- 1. Friedman S. Previvor: past, present, & future. FORCE: Facing Our Risk of Cancer. Empowered, July 22 2008 (updated September 28, 2016).
- 2. You YN, Lakhani VT, Wells SA, Jr. The role of prophylactic surgery in cancer prevention. World J Surg. 2007;31(3):450-64.
- 3. Daly MB, Axilbund JE, Buys S, Crawford B, Farrell CD, Friedman S, et al. Genetic/familial high-risk assessment: breast and ovarian. Journal of the National Comprehensive Cancer Network. 2010;8(5):562-94.
- 4. Fritzell K, Persson C, Bjork J, Hultcrantz R, Wettergren L. Patients’ views of surgery and surveillance for familial adenomatous polyposis. Cancer Nursing. 2010;33(2):E17-23.
- 5. Oei AL, Massuger LF, Bulten J, Ligtenberg MJ, Hoogerbrugge N, de Hullu JA. Surveillance of women at high risk for hereditary ovarian cancer is inefficient. British Journal of Cancer. 2006;94(6):814-9.
- 6. Bermejo-Perez MJ, Marquez-Calderon S, Llanos-Mendez A. Effectiveness of preventive interventions in BRCA1/2 gene mutation carriers: a systematic review. International Journal of Cancer. 2007;121(2):225-31.
- 7. American College of O, Gynecologists, Bulletins--Gynecology ACoP, Genetics ACo, Society of Gynecologic O. ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome. Obstetrics and Gynecology. 2009;113(4):957-66.
- 8. Dhar SU, Cooper HP, Wang T, Parks B, Staggs SA, Hilsenbeck S, et al. Significant differences among physician specialties in management recommendations of BRCA1 mutation carriers. Breast Cancer Res Treat. 2011;129(1):221-7.
- 9. O’Neill SC, Valdimarsdottir HB, Demarco TA, Peshkin BN, Graves KD, Brown K, et al. BRCA1/2 test results impact risk management attitudes, intentions, and uptake. Breast Cancer Res Treat. 2010;124(3):755-64.
- 10. Printz C. New data on BRCA mutations and prophylactic surgeries. Cancer. 2011;117(4):657.
- 11. van Dijk S, van Roosmalen MS, Otten W, Stalmeier PF. Decision making regarding prophylactic mastectomy: stability of preferences and the impact of anticipated feelings of regret. Journal of Clinical Oncology. 2008;26(14):2358-63.
- 12. Klitzman R, Chung W. The process of deciding about prophylactic surgery for breast and ovarian cancer: Patient questions, uncertainties, and communication. American Journal of Medical Genetics Part A. 2010;152A(1):52-66.
- 13. Sigal BM, Munoz DF, Kurian AW, Plevritis SK. A simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2012;21(7):1066-77.
- 14. Ehrenreich B. Slap on a pink ribbon, call it a day. Salon. Dec 2 2009.
- 15. Yadlon S. Skinny women and good mothers: the rhetoric of risk, control, and culpability in the production of knowledge about breast cancer. Feminist Studies. 1997;23(3):645-677.
- 16. Blanchard D, Erblich J, Montgomery GH, Bovbjerg DH. Read all about it: the over-representation of breast cancer in popular magazines. Prev Med. 2002;35(4):343-8.
- 17. Clarke JN, Everest MM. Cancer in the mass print media: fear, uncertainty and the medical model. Social Science & Medicine. 2006;62(10):2591-600.
- 18. Andsager JL, Hust SJ, Powers A. Patient-blaming and representation of risk factors in breast cancer images. Women Health. 2000;31(2-3):57-79.
- 19. Haas JS, Kaplan CP, Des Jarlais G, Gildengoin V, Perez-Stable EJ, Kerlikowske K. Perceived risk of breast cancer among women at average and increased risk. Journal of Women’s Health. 2005;14(9):845-51.
- 20. U.S. Department of Health & Human Services. Women’s fear of heart disease has almost doubled in three years, but breast cancer remains most feared disease. About the Heart Truth, NIH. Feb 29 2012.
- 21. Lock M. Human body parts as therapeutic tools: contradictory discourses and transformed subjectivities. Qualitative Health Research. 2002;12(10):1406-18.
- 22. Swindell JS. Facial allograft transplantation, personal identity and subjectivity. Journal of Medical Ethics. 2007;33(8):449-53.
- 23. Kenen RH, Shapiro PJ, Hantsoo L, Friedman S, Coyne JC. Women with BRCA1 or BRCA2 mutations renegotiating a post-prophylactic mastectomy identity: self-image and self-disclosure. Journal of Genetic Counseling. 2007;16(6):789-98.
- 24. Andrews L, Mireskandari S, Jessen J, Thewes B, Solomon M, Macrae F, et al. Impact of familial adenomatous polyposis on young adults: quality of life outcomes. Dis Colon Rectum. 2007;50(9):1306-15.
- 25. Wiseman S. From the luxurious breast to the virtuous breast: the body politic transformed. Textual Practice. 1997;11(3):477-92.
- 26. Campo-Engelstein L. Consistency in insurance coverage for iatrogenic conditions resulting from cancer treatment including fertility preservation. Journal of Clinical Oncology. 2010;28(8):1284-6.